Immediate sequential bilateral cataract surgery argument tops recent cataract articles
The most-viewed cataract surgery items on Healio/OSN in May include an argument for immediate sequential bilateral cataract surgery, articles on patient satisfaction and two video perspectives.
Here are the most popular pieces on cataract surgery from May:
Surgeons should consider offering immediate sequential bilateral cataract surgery
Immediate sequential bilateral cataract surgery can offer similar vision and safety outcomes when compared with delayed sequential bilateral cataract surgery and is a more cost-effective option for patients and the health care system, according to a speaker at the virtual American Society of Cataract and Refractive Surgery meeting. Read more.
Time is right for intraocular delivery of steroid after cataract surgery
Controlling inflammation after cataract surgery is of paramount importance, and this is just as much the case for routine low-risk surgeries as it is for complicated or high-risk procedures. Patients today have high expectations of cataract surgery, and providing potent, immediate inflammation control postoperatively is essential to ensuring a positive experience. Read more.
VIDEO: Trifocal IOL receives high patient satisfaction scores
In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, John A. Hovanesian, MD, FACS, discusses a study showing high patient satisfaction in those implanted bilaterally with the Alcon PanOptix trifocal IOL. Watch here.
VIDEO: Intracameral cataract surgery treatment bests postop topical steroid regimen
In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, Denise Visco, MD, MBA, discusses the study she is presenting comparing the Omidria intracameral phenylephrine/ketorolac combination (Omeros) with NSAIDs compared with a postoperative topical steroid and NSAID regimen. Watch here.
Patient, physician satisfaction high for Dextenza after cataract surgery
High visualization, ease of use and greater pain reduction for up to 30 days after cataract surgery led to higher patient and physician ratings for Dextenza compared with placebo. Read more.